drugset / Trial / NCT02851407

Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients

NCT02851407

Phase 3 Completed 372 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupOpen-labelPrevention

Summary

This study is to compare the efficacy and safety of defibrotide prophylaxis in addition to best supportive care versus best supportive care alone in the prevention of hepatic veno- occlusive disease (VOD) in adult and pediatric patients undergoing hematopoietic stem cell transplant who are at high risk or very high risk of developing VOD.

Timeline

Start
2016-09-01
Primary completion
2020-10-20
Completion
2020-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Defibrotide Oligonucleotide (other) 6.25 mg/kg Intravenous